simvastatin actavis filmuhúðuð tafla 20 mg
actavis group ptc ehf. - simvastatinum inn - filmuhúðuð tafla - 20 mg
simvastatin actavis filmuhúðuð tafla 40 mg
actavis group ptc ehf. - simvastatinum inn - filmuhúðuð tafla - 40 mg
simvastatín alvogen (simvastatín portfarma) filmuhúðuð tafla 20 mg
alvogen ehf. - simvastatinum inn - filmuhúðuð tafla - 20 mg
simvastatín alvogen (simvastatín portfarma) filmuhúðuð tafla 40 mg
alvogen ehf. - simvastatinum inn - filmuhúðuð tafla - 40 mg
solu-cortef stungulyfsstofn og leysir, lausn 100 mg
pfizer aps - hydrocortisonum natríumsúkkínat - stungulyfsstofn og leysir, lausn - 100 mg
solu-cortef stungulyfsstofn og leysir, lausn 250 mg
pfizer aps - hydrocortisonum natríumsúkkínat - stungulyfsstofn og leysir, lausn - 250 mg
solu-medrol stungulyfsstofn og leysir, lausn 40 mg
pfizer aps - methylprednisolonum natríumsúkkínat - stungulyfsstofn og leysir, lausn - 40 mg
ztalmy
marinus pharmaceuticals emerald limited - ganaxolone - epileptic syndromes; spasms, infantile - Önnur antiepileptics - ztalmy is indicated for the adjunctive treatment of epileptic seizures associated with cyclin-dependent kinase-like 5 (cdkl5) deficiency disorder (cdd) in patients 2 to 17 years of age. ztalmy may be continued in patients 18 years of age and older.
solu-medrol stungulyfsstofn og leysir, lausn 125 mg
pfizer aps - methylprednisolonum natríumsúkkínat - stungulyfsstofn og leysir, lausn - 125 mg
solu-medrol stungulyfsstofn og leysir, lausn 500 mg
pfizer aps - methylprednisolonum natríumsúkkínat - stungulyfsstofn og leysir, lausn - 500 mg